Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 48

1.

TLR7 Protein Expression in Mild and Severe Lupus-Prone Models Is Regulated in a Leukocyte, Genetic, and IRAK4 Dependent Manner.

Celhar T, Lu HK, Benso L, Rakhilina L, Lee HY, Tripathi S, Zharkova O, Ong WY, Yasuga H, Au B, Marlier D, Lim LHK, Thamboo TP, Mudgett JS, Mackey MF, Zaller DM, Connolly JE, Fairhurst AM.

Front Immunol. 2019 Jul 10;10:1546. doi: 10.3389/fimmu.2019.01546. eCollection 2019.

2.

A human tissue-based functional assay platform to evaluate the immune function impact of small molecule inhibitors that target the immune system.

St Pierre C, Guo J, Shin JD, Engstrom LW, Lee HH, Herbert A, Surdi L, Baker J, Salmon M, Shah S, Ellis JM, Houshyar H, Crackower MA, Kleinschek MA, Jones DC, Hicks A, Zaller DM, Alves SE, Ramadas RA.

PLoS One. 2017 Jul 18;12(7):e0180870. doi: 10.1371/journal.pone.0180870. eCollection 2017.

3.

Inhibition of spleen tyrosine kinase attenuates IgE-mediated airway contraction and mediator release in human precision cut lung slices.

Koziol-White CJ, Jia Y, Baltus GA, Cooper PR, Zaller DM, Crackower MA, Sirkowski EE, Smock S, Northrup AB, Himes BE, Alves SE, Panettieri RA Jr.

Br J Pharmacol. 2016 Nov;173(21):3080-3087. doi: 10.1111/bph.13550. Epub 2016 Oct 5.

4.

Pharmacological Inhibition of O-GlcNAcase Does Not Increase Sensitivity of Glucocorticoid Receptor-Mediated Transrepression.

Stivers PJ, Harmonay L, Hicks A, Mehmet H, Morris M, Robinson GM, Strack PR, Savage MJ, Zaller DM, Zwierzynski I, Brandish PE.

PLoS One. 2015 Dec 15;10(12):e0145151. doi: 10.1371/journal.pone.0145151. eCollection 2015.

5.

Pillars article: Transgenic mice that express a myelin basic protein-specific T cell receptor develop spontaneous autoimmunity. Cell. 1993. 72: 551-560.

Goverman J, Woods A, Larson L, Weiner LP, Hood L, Zaller DM.

J Immunol. 2013 Apr 1;190(7):3018-27. No abstract available.

6.

Production of a human neutralizing monoclonal antibody and its crystal structure in complex with ectodomain 3 of the interleukin-13 receptor α1.

Redpath NT, Xu Y, Wilson NJ, Fabri LJ, Baca M, Andrews AE, Braley H, Lu P, Ireland C, Ernst RE, Woods A, Forrest G, An Z, Zaller DM, Strohl WR, Luo CS, Czabotar PE, Garrett TP, Hilton DJ, Nash AD, Zhang JG, Nicola NA.

Biochem J. 2013 Apr 15;451(2):165-75. doi: 10.1042/BJ20121819.

PMID:
23384096
7.

Evidence for cyclic diguanylate as a vaccine adjuvant with novel immunostimulatory activities.

Gray PM, Forrest G, Wisniewski T, Porter G, Freed DC, DeMartino JA, Zaller DM, Guo Z, Leone J, Fu TM, Vora KA.

Cell Immunol. 2012 Jul-Aug;278(1-2):113-9. doi: 10.1016/j.cellimm.2012.07.006. Epub 2012 Aug 4.

PMID:
23121983
8.

FGF21 analogs of sustained action enabled by orthogonal biosynthesis demonstrate enhanced antidiabetic pharmacology in rodents.

Mu J, Pinkstaff J, Li Z, Skidmore L, Li N, Myler H, Dallas-Yang Q, Putnam AM, Yao J, Bussell S, Wu M, Norman TC, Rodriguez CG, Kimmel B, Metzger JM, Manibusan A, Lee D, Zaller DM, Zhang BB, DiMarchi RD, Berger JP, Axelrod DW.

Diabetes. 2012 Feb;61(2):505-12. doi: 10.2337/db11-0838. Epub 2011 Dec 30.

9.

Disubstituted pyrimidines as Lck inhibitors.

Hunt JA, Beresis RT, Goulet JL, Holmes MA, Hong XJ, Kovacs E, Mills SG, Ruzek RD, Wong F, Hermes JD, Park YW, Salowe SP, Sonatore LM, Wu L, Woods A, Zaller DM, Sinclair PJ.

Bioorg Med Chem Lett. 2009 Sep 15;19(18):5440-3. doi: 10.1016/j.bmcl.2009.07.102. Epub 2009 Jul 25.

PMID:
19674899
10.

Genetic ablation or pharmacological blockade of dipeptidyl peptidase IV does not impact T cell-dependent immune responses.

Vora KA, Porter G, Peng R, Cui Y, Pryor K, Eiermann G, Zaller DM.

BMC Immunol. 2009 Apr 9;10:19. doi: 10.1186/1471-2172-10-19.

11.

Synthesis and biological activity of quinolinone and dihydroquinolinone p38 MAP kinase inhibitors.

Chen MH, Fitzgerald P, Singh SB, O'Neill EA, Schwartz CD, Thompson CM, O'Keefe SJ, Zaller DM, Doherty JB.

Bioorg Med Chem Lett. 2008 Mar 15;18(6):2222-6. doi: 10.1016/j.bmcl.2006.10.097. Epub 2006 Nov 6.

PMID:
18316187
12.

Chemical genetics define the roles of p38alpha and p38beta in acute and chronic inflammation.

O'Keefe SJ, Mudgett JS, Cupo S, Parsons JN, Chartrain NA, Fitzgerald C, Chen SL, Lowitz K, Rasa C, Visco D, Luell S, Carballo-Jane E, Owens K, Zaller DM.

J Biol Chem. 2007 Nov 30;282(48):34663-71. Epub 2007 Sep 13.

13.

Characterization of the NOD/scid-[Tg]DR1 mouse expressing HLA-DRB1*01 transgene: a model of SCID-hu mouse for vaccine development.

Camacho RE, Wnek R, Fischer P, Shah K, Zaller DM, Woods A, La Monica N, Aurisicchio L, Fitzgerald-Bocarsly P, Koo GC.

Exp Hematol. 2007 Aug;35(8):1219-30.

PMID:
17662890
14.

The discovery of a potent and selective lethal factor inhibitor for adjunct therapy of anthrax infection.

Xiong Y, Wiltsie J, Woods A, Guo J, Pivnichny JV, Tang W, Bansal A, Cummings RT, Cunningham BR, Friedlander AM, Douglas CM, Salowe SP, Zaller DM, Scolnick EM, Schmatz DM, Bartizal K, Hermes JD, MacCoss M, Chapman KT.

Bioorg Med Chem Lett. 2006 Feb 15;16(4):964-8. Epub 2005 Dec 9.

PMID:
16338135
15.

p38 MAP kinase inhibitors: metabolically stabilized piperidine-substituted quinolinones and naphthyridinones.

Bao J, Hunt JA, Miao S, Rupprecht KM, Stelmach JE, Liu L, Ruzek RD, Sinclair PJ, Pivnichny JV, Hop CE, Kumar S, Zaller DM, Shoop WL, O'neill EA, O'keefe SJ, Thompson CM, Cubbon RM, Wang R, Zhang WX, Thompson JE, Doherty JB.

Bioorg Med Chem Lett. 2006 Jan 1;16(1):64-8. Epub 2005 Oct 18.

PMID:
16242322
16.

Intra-thymic/splenic engraftment of human T cells in HLA-DR1 transgenic NOD/scid mice.

Camacho RE, Wnek R, Shah K, Zaller DM, O'Reilly RJ, Collins N, Fitzgerald-Bocarsly P, Koo GC.

Cell Immunol. 2004 Nov-Dec;232(1-2):86-95. Epub 2005 Apr 19.

PMID:
15922719
17.

Anthrax lethal factor inhibition.

Shoop WL, Xiong Y, Wiltsie J, Woods A, Guo J, Pivnichny JV, Felcetto T, Michael BF, Bansal A, Cummings RT, Cunningham BR, Friedlander AM, Douglas CM, Patel SB, Wisniewski D, Scapin G, Salowe SP, Zaller DM, Chapman KT, Scolnick EM, Schmatz DM, Bartizal K, MacCoss M, Hermes JD.

Proc Natl Acad Sci U S A. 2005 May 31;102(22):7958-63. Epub 2005 May 23.

18.

Novel ketal ligands for the glucocorticoid receptor: in vitro and in vivo activity.

Smith CJ, Ali A, Balkovec JM, Graham DW, Hammond ML, Patel GF, Rouen GP, Smith SK, Tata JR, Einstein M, Ge L, Harris GS, Kelly TM, Mazur P, Thompson CM, Wang CF, Williamson JM, Miller DK, Pandit S, Santoro JC, Sitlani A, Yamin TT, O'Neill EA, Zaller DM, Carballo-Jane E, Forrest MJ, Luell S.

Bioorg Med Chem Lett. 2005 Jun 2;15(11):2926-31.

PMID:
15911283
19.

Novel N-arylpyrazolo[3,2-c]-based ligands for the glucocorticoid receptor: receptor binding and in vivo activity.

Ali A, Thompson CF, Balkovec JM, Graham DW, Hammond ML, Quraishi N, Tata JR, Einstein M, Ge L, Harris G, Kelly TM, Mazur P, Pandit S, Santoro J, Sitlani A, Wang C, Williamson J, Miller DK, Thompson CM, Zaller DM, Forrest MJ, Carballo-Jane E, Luell S.

J Med Chem. 2004 May 6;47(10):2441-52.

PMID:
15115388
20.
21.

SAR of 3,4-dihydropyrido[3,2-d]pyrimidone p38 inhibitors.

Liu L, Stelmach JE, Natarajan SR, Chen MH, Singh SB, Schwartz CD, Fitzgerald CE, O'Keefe SJ, Zaller DM, Schmatz DM, Doherty JB.

Bioorg Med Chem Lett. 2003 Nov 17;13(22):3979-82.

PMID:
14592489
22.
23.

p38 Inhibitors: piperidine- and 4-aminopiperidine-substituted naphthyridinones, quinolinones, and dihydroquinazolinones.

Hunt JA, Kallashi F, Ruzek RD, Sinclair PJ, Ita I, McCormick SX, Pivnichny JV, Hop CE, Kumar S, Wang Z, O'Keefe SJ, O'Neill EA, Porter G, Thompson JE, Woods A, Zaller DM, Doherty JB.

Bioorg Med Chem Lett. 2003 Feb 10;13(3):467-70.

PMID:
12565952
24.

Specific stimulation of MHC-transgenic mouse T-cell hybridomas with xenogeneic APC.

Vidovic D, Graddis TJ, Stepan LP, Zaller DM, Laus R.

Hum Immunol. 2003 Feb;64(2):238-44.

PMID:
12559626
25.

Hybrid-designed inhibitors of p38 MAP kinase utilizing N-arylpyridazinones.

Colletti SL, Frie JL, Dixon EC, Singh SB, Choi BK, Scapin G, Fitzgerald CE, Kumar S, Nichols EA, O'Keefe SJ, O'Neill EA, Porter G, Samuel K, Schmatz DM, Schwartz CD, Shoop WL, Thompson CM, Thompson JE, Wang R, Woods A, Zaller DM, Doherty JB.

J Med Chem. 2003 Jan 30;46(3):349-52.

PMID:
12540232
26.

Design and synthesis of potent, orally bioavailable dihydroquinazolinone inhibitors of p38 MAP kinase.

Stelmach JE, Liu L, Patel SB, Pivnichny JV, Scapin G, Singh S, Hop CE, Wang Z, Strauss JR, Cameron PM, Nichols EA, O'Keefe SJ, O'Neill EA, Schmatz DM, Schwartz CD, Thompson CM, Zaller DM, Doherty JB.

Bioorg Med Chem Lett. 2003 Jan 20;13(2):277-80.

PMID:
12482439
27.

p38MAP kinase inhibitors. Part 1: design and development of a new class of potent and highly selective inhibitors based on 3,4-dihydropyrido[3,2-d]pyrimidone scaffold.

Natarajan SR, Wisnoski DD, Singh SB, Stelmach JE, O'Neill EA, Schwartz CD, Thompson CM, Fitzgerald CE, O'Keefe SJ, Kumar S, Hop CE, Zaller DM, Schmatz DM, Doherty JB.

Bioorg Med Chem Lett. 2003 Jan 20;13(2):273-6.

PMID:
12482438
28.

Staging and resetting T cell activation in SMACs.

Freiberg BA, Kupfer H, Maslanik W, Delli J, Kappler J, Zaller DM, Kupfer A.

Nat Immunol. 2002 Oct;3(10):911-7. Epub 2002 Sep 3.

PMID:
12244310
30.
31.

Role of APC in the selection of immunodominant T cell epitopes.

Ma C, Whiteley PE, Cameron PM, Freed DC, Pressey A, Chen SL, Garni-Wagner B, Fang C, Zaller DM, Wicker LS, Blum JS.

J Immunol. 1999 Dec 15;163(12):6413-23.

32.

Homogeneous proximity tyrosine kinase assays: scintillation proximity assay versus homogeneous time-resolved fluorescence.

Park YW, Cummings RT, Wu L, Zheng S, Cameron PM, Woods A, Zaller DM, Marcy AI, Hermes JD.

Anal Biochem. 1999 Apr 10;269(1):94-104.

PMID:
10094779
34.

Secondary structure composition and pH-dependent conformational changes of soluble recombinant HLA-DM.

Busch R, Reich Z, Zaller DM, Sloan V, Mellins ED.

J Biol Chem. 1998 Oct 16;273(42):27557-64.

35.

Induction of autoimmune arthritis in HLA-DR4 (DRB1*0401) transgenic mice by immunization with human and bovine type II collagen.

Rosloniec EF, Brand DD, Myers LK, Esaki Y, Whittington KB, Zaller DM, Woods A, Stuart JM, Kang AH.

J Immunol. 1998 Mar 15;160(6):2573-8.

36.

X-ray crystal structure of HLA-DR4 (DRA*0101, DRB1*0401) complexed with a peptide from human collagen II.

Dessen A, Lawrence CM, Cupo S, Zaller DM, Wiley DC.

Immunity. 1997 Oct;7(4):473-81.

37.

An HLA-DR1 transgene confers susceptibility to collagen-induced arthritis elicited with human type II collagen.

Rosloniec EF, Brand DD, Myers LK, Whittington KB, Gumanovskaya M, Zaller DM, Woods A, Altmann DM, Stuart JM, Kang AH.

J Exp Med. 1997 Mar 17;185(6):1113-22.

38.

Naturally processed T cell epitopes from human glutamic acid decarboxylase identified using mice transgenic for the type 1 diabetes-associated human MHC class II allele, DRB1*0401.

Wicker LS, Chen SL, Nepom GT, Elliott JF, Freed DC, Bansal A, Zheng S, Herman A, Lernmark A, Zaller DM, Peterson LB, Rothbard JB, Cummings R, Whiteley PJ.

J Clin Invest. 1996 Dec 1;98(11):2597-603.

39.

Transgenic mouse models of experimental autoimmune encephalomyelitis.

Zaller DM, Sloan VS.

Curr Top Microbiol Immunol. 1996;206:15-31. Review. No abstract available.

PMID:
8608716
40.

Lyme disease in human DR4Dw4-transgenic mice.

Feng S, Barthold SW, Bockenstedt LK, Zaller DM, Fikrig E.

J Infect Dis. 1995 Jul;172(1):286-9.

PMID:
7797933
41.

Mediation by HLA-DM of dissociation of peptides from HLA-DR.

Sloan VS, Cameron P, Porter G, Gammon M, Amaya M, Mellins E, Zaller DM.

Nature. 1995 Jun 29;375(6534):802-6.

PMID:
7596415
42.

Human major histocompatibility complex class II-restricted T cell responses in transgenic mice.

Woods A, Chen HY, Trumbauer ME, Sirotina A, Cummings R, Zaller DM.

J Exp Med. 1994 Jul 1;180(1):173-81.

43.

Transgenic mice that express a myelin basic protein-specific T cell receptor develop spontaneous autoimmunity.

Goverman J, Woods A, Larson L, Weiner LP, Hood L, Zaller DM.

Cell. 1993 Feb 26;72(4):551-60.

PMID:
7679952
44.
45.
46.

Autoimmune disease and T-cell immunologic recognition.

Hood L, Kumar V, Osman G, Beall SS, Gomez C, Funkhouser W, Kono DH, Nickerson D, Zaller DM, Urban JL.

Cold Spring Harb Symp Quant Biol. 1989;54 Pt 2:859-74. Review. No abstract available.

PMID:
2484250
48.

Supplemental Content

Loading ...
Support Center